Azafaros Raises $150M to Target Rare Neuro-Metabolic Diseases

Azafaros will use the Series B haul to push lead asset nizubaglustat into late-stage studies for Niemann-Pick disease Type C and GM1/GM2 gangliosidoses later this year.